Eyenovia (NSDQ:EYEN) announced today that it appointed renowned ophthalmologist Dr. Julia Haller to its board of directors.
New York-based Eyenovia adds the experienced Haller to its board as it continues to develop the MydCombi fixed-combination mydriatic agent for potential use in comprehensive eye exams with a formulation for touchless fixed-combination microdosing to improve the patient experience.
“We are delighted to welcome Dr. Haller to our Board of Directors at such an exciting time for Eyenovia,” Eyenovia CEO & CMO Dr. Sean Ianchulev said in a news release. “We believe that Dr. Haller’s decades of experience as an esteemed ophthalmic surgeon, scientist, professor, and business leader will be invaluable to the Eyenovia team as we strive to advance our late-stage ophthalmic pipeline and work towards our near-term clinical and regulatory milestones.”
Haller has held the role of ophthalmologist-in-chief at Wills Eye Hospital in Philadelphia since 2007, while also serving as a professor and chair of the dept. of ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University and Thomas Jefferson University Hospitals.
She also serves on the board of directors at Bristol-Myers Squibb. She is also president and a board member for the Women in Medicine Legacy Foundation, among a series of other roles, both past and present.
“I have been familiar with Eyenovia and its MAP technology for some time now and believe the Company’s proprietary programs have the potential to become new standards of care in ophthalmic indications with significant unmet needs,” Haller said. “I look forward to working with my fellow Eyenovia Board members and the leadership team to help create advances in the field.”
